A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
Not Applicable
Completed
- Conditions
- HIV InfectionsCytomegalovirus Retinitis
- Registration Number
- NCT00002432
- Lead Sponsor
- Astra USA
- Brief Summary
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS patients experiencing their first episode of cytomegalovirus (CMV) retinitis. To evaluate the safety and efficacy of foscarnet maintenance therapy for treatment of AIDS patients experiencing CMV retinitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie foscarnet's antiviral activity against CMV in AIDS patients?
How does foscarnet compare to ganciclovir in treating CMV retinitis in HIV-infected individuals?
Which biomarkers correlate with treatment response to foscarnet in CMV retinitis of immunocompromised patients?
What are the most common adverse events associated with foscarnet therapy for CMV retinitis in AIDS populations?
Are there combination therapies involving foscarnet that improve outcomes for CMV retinitis in HIV patients compared to monotherapy?
Trial Locations
- Locations (1)
Davies Med Ctr
🇺🇸San Francisco, California, United States
Davies Med Ctr🇺🇸San Francisco, California, United States